Want to join the conversation?
As part of a partnership with $AZN & MedImmune, $CELG said it has launched the FUSION clinical development program of durvalumab (MEDI4736), a monoclonal antibody designed for the treatment of cancer. This program is to develop & commercialize durvalumab across a range of blood cancers & will include four studies.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.